D. Western Therapeutics Institute News

D. Western Therapeutics Institute: Consolidated financial results for the six-month period ended June 30, 2024 (based on Japanese accounting standards).

Aug 9 16:00

D. Western Therapeutics Institute: Announcements of monthly exercise status for the 12th subscription rights (with exercise price adjustment clause).

Aug 1 14:30

D. Western Therapeutics Institute: Policy regarding the re-application of the nerve pain treatment drug "DW-5LBT".

Jul 16 07:30

D. Western Therapeutics Institute: Announcements of individual stocks: Notification of Receipt of Approval Notification for Neurological Pain Treatment Drug, DW-5LBT.

Jul 12 07:30

D. Western Therapeutics Institute: Announcement of the mass exercise of the 12th subscription rights (with exercise price adjustment clause).

Jul 1 14:30

D. Western Therapeutics Institute: Announcements of monthly exercise status for the 12th subscription rights (with exercise price adjustment clause).

Jul 1 14:30

D.WESTERN THERAPEUTICS INST: Consolidated financial results for the three months ended 2024/3/31 (based on Japanese accounting standards)

May 13 14:30

D. Western Therapeutics Institute: Corporate Governance Report

Mar 27 14:35

D.Western Therapeutics Institute: Notice of Submission of Clinical Trial Plan Notification for Regenerative Medicine Cell Product “DWR-2206”

Mar 27 14:00

D. Western Therapeutics Institute: [Delayed]Consolidated Financial Results for the Fiscal Year Ended December 31, 2023 (Based on Japanese GAAP)

Feb 14 07:45

D. Western Therapeutics Institute: Matters relating to business plans and growth potential

Feb 9 14:30

D. Western Therapeutics Institute: Notice of acceptance of the application for approval of the nerve pain medication “DW-5LBT” in the United States

Jan 31 14:00

D. Western Therapeutics Institute: Application for approval of the nerve pain medication “DW-5LBT”

Jan 12 14:30

D. Western Therapeutics Institute: Independent Officer Registration Form

Jan 5 16:00

D. Western Therapeutics Institute: When to apply for approval for the nerve pain medication “DW-5LBT”

Dec 25, 2023 07:30

D. Western Therapeutics Institute: Notice of resignation of director who is a member of the Audit and Supervisory Committee

Dec 15, 2023 14:30

D. Western Therapeutics Institute: [Delayed]Summary of Consolidated Financial Results for the Nine Months Ended September 30, 2023(Based on Japanese GAAP)

Nov 13, 2023 11:15

D. Western Therapeutics Institute: Prospects for reapplying for the nerve pain treatment drug “DW-5LBT”

Oct 10, 2023 14:00

D. Western Therapeutics Institute: Notice of receipt of the examination completion report notification for the nerve pain treatment drug “DW-5LBT”

Sep 29, 2023 07:30

D. Western Therapeutics Institute: Notice of commencement of administration of the glaucoma drug “H-1337” to test subjects in the late US phase II clinical trial

Aug 29, 2023 07:15